MS	Multiple Sclerosis
RRMS	Relapsing-Remitting Multiple Sclerosis
CDP	Confirmed Disability Progression
CNS	Central Nervous System
EDSS	Expanded Disability Status Scale
DMT	Disease-Modifying Therapy
MRI	Magnetic Resonance Imaging
T2-w/T1-w	T2-weighted/T1-weighted
GELs	Gadolinium-Enhancing Lesions
NEDA-3	No Evidence of Disease Activity-3
IRRs	Infusion-Related Reactions
AE/AEs	Adverse Event/s
SC	Subcutaneous
RCT	Randomized Controlled Trial
ARR	Annual Relapse Rate
RWE	Real-World Evidence
HETA	High-Efficacy Treatment Agents
mAb	Monoclonal Antibody
HSV	Herpes Simplex Virus